Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Mobile-Based Telemedicine and Health-Related Quality of Life Among Patients With Chronic Heart Failure (MOBILE-HF) (MOBILE-HF)

15 de junio de 2026 actualizado por: Gudisa Bereda, Select College

Effectiveness of Mobile-Based Telemedicine on Health-Related Quality of Life Among Patients With Chronic Heart Failure: Protocol for a Quasi-Experimental Study

Chronic heart failure (CHF) is a long-term condition in which the heart is unable to pump blood effectively. It can cause symptoms such as shortness of breath, fatigue, swelling in the legs, and reduced ability to perform daily activities. These problems often reduce a patient's quality of life and may lead to frequent hospital visits.

This study will assess whether a mobile-based telemedicine program can improve the health-related quality of life of patients with chronic heart failure in Ethiopia.

In this study, 70 adult patients with chronic heart failure will be included. They will be divided into two groups: 35 patients will receive routine care plus mobile-based telemedicine support, and 35 patients will receive routine care only.

The mobile-based telemedicine program will include health education, medication reminders, lifestyle advice, and follow-up support delivered through phone calls and text messages over an 8-week period.

Patients' quality of life will be measured at the beginning of the study and again after 8 weeks using a standard questionnaire called the Minnesota Living with Heart Failure Questionnaire (MLHFQ).

The main goal of the study is to determine whether mobile-based telemedicine improves quality of life compared with routine care alone. The study may also help improve self-care behaviors, medication adherence, and symptom control among patients with heart failure.

The findings may provide evidence to support the use of mobile health technologies as a simple and scalable approach to improve heart failure care in Ethiopia.

Descripción general del estudio

Descripción detallada

Chronic heart failure (CHF) is a long-term cardiovascular condition that significantly impairs functional capacity and quality of life. Patients often experience persistent symptoms, reduced daily activity, and frequent hospital visits, particularly in settings with limited access to continuous follow-up care.

This study will evaluate the effectiveness of a mobile-based telemedicine intervention on health-related quality of life among CHF patients attending follow-up care at Menelik II Comprehensive Specialized Hospital, Addis Ababa, Ethiopia.

A quasi-experimental design with a nonequivalent control group pre-test and post-test approach will be used. A total of 70 eligible adult CHF patients will be included and assigned to either an intervention group (n = 35) or a comparison group (n = 35).

The intervention group will receive an 8-week mobile-based telemedicine program in addition to routine care. The program includes scheduled phone calls, text messages, and WhatsApp-based communication providing education, self-care guidance, medication adherence support, lifestyle modification advice, and symptom monitoring. The comparison group will receive routine standard care only.

Health-related quality of life will be measured at baseline and after 8 weeks using the Minnesota Living with Heart Failure Questionnaire (MLHFQ). The main outcome is the change in HRQoL between the two groups after the intervention period.

Data will be analyzed to determine the effect of the intervention on quality of life outcomes.

This study is expected to provide evidence on whether mobile-based telemedicine can improve patient-reported outcomes in CHF management and support its integration into routine cardiac care in resource-limited settings.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

72

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Gudisa Bereda, B.Pharm, MPH cand
  • Número de teléfono: +251-913118492
  • Correo electrónico: gudisabareda95@gmail.com

Copia de seguridad de contactos de estudio

  • Nombre: Javed Ahamad, Professor
  • Número de teléfono: 07512372960
  • Correo electrónico: jas.hamdard@gmail.com

Ubicaciones de estudio

      • Addis Ababa, Etiopía
        • Reclutamiento
        • Menelik II Comprehensive Specialized Hospital
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Descripción

Inclusion Criteria:

  • Adults aged 18-65 years who will be diagnosed with CHF (NYHA class II⁃III)
  • Patients with reduced left ventricular ejection fraction LVEF ≤ 40%
  • Patient who will have access to a mobile phone and will be able to use it
  • Patients who will be able to communicate in Amharic, Oromic, or English
  • Patients who will provide written informed consent
  • Patients who will be diagnosed with HF lasting ≥ 6 months, to be confirmed by echocardiography and clinical assessment
  • Patients with no contraindications for mild to moderate physical activity

Exclusion Criteria:

  • Patients with NYHA class IV or who will require intensive care at enrollment
  • Patients with other severe medical conditions (e.g., end-stage renal disease, & end stage liver disease)
  • Patients with severe cognitive impairment or psychiatric illness that will interfere with participation
  • Patients already enrolled in another telemedicine or intervention study
  • Pregnant and lactating women

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Cuidados de apoyo
  • Asignación: No aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Mobile-Based Telemedicine + Routine Care

Arm 1 Arm Name: Intervention Group (Mobile-Based Telemedicine + Routine Care)

Description:

Participants in this arm will receive routine heart failure care provided at the cardiac clinic in addition to an 8-week mobile-based telemedicine intervention.

Intervention(s):

Behavioral Intervention: Mobile-Based Telemedicine Scheduled mobile phone calls SMS/text messages WhatsApp-based educational messages Health education on heart failure management Medication adherence support Diet and lifestyle counseling Symptom monitoring and follow-up support

Health-related quality of life will be assessed using the Minnesota Living with Heart Failure Questionnaire (MLHFQ).
Comparador activo: Routine Care Only

Arm 2 Arm Name: Control Group (Routine Care)

Description:

Participants in this arm will receive standard routine heart failure care provided at the cardiac clinic without additional mobile-based telemedicine support.

Intervention(s):

Standard Clinical Care Routine follow-up visits Usual medical management for chronic heart failure

Health-related quality of life will be assessed using the Minnesota Living with Heart Failure Questionnaire (MLHFQ).

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Health-Related Quality of Life (HRQoL)
Periodo de tiempo: Baseline and 8 weeks after intervention
Health-related quality of life will be assessed using the Minnesota Living with Heart Failure Questionnaire (MLHFQ). The MLHFQ is a 21-item validated disease-specific instrument for patients with chronic heart failure. Each item is rated on a 6-point Likert scale ranging from 0 (no impact) to 5 (very much impact), with total scores ranging from 0 to 105. Lower scores indicate better quality of life. The primary outcome will be the change in MLHFQ total score from baseline to 8-week follow-up between the intervention and control groups.
Baseline and 8 weeks after intervention

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Investigadores

  • Investigador principal: Gudisa Bereda, Marie Stopes International Ethiopia, Ambo, Ethiopia

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Publicaciones Generales

  • References 1. Kalwani NM, Koos H, Kohn E, et al. Impact of Initial Cardiology Telemedicine Evaluation on Follow-Up Visits for Common Conditions: Quasi-Experimental Study. J Med Internet Res. 2025;27(e73509). 2. Gomez T, Anaya YB, Shih KJ, et al. A qualitative study of primary care physicians' experiences with telemedicine during COVID-19. J Am Board Fam Med. 2021;34: S61-S70. 3. Joshi M, Koos HT, Sandhu A, et al. Impact of clinician telemedicine use on new medication orders for patients with heart failure with reduced ejection fraction. J Am Coll Cardiol. 2024;83(13):632. 4. Arian M, Valinejadi A, Soleimani M. Quality of Life in Heart Patients Receiving Telerehabilitation: An Overview with Meta-Analyses. Iran J Public Health. 2022;51(11):2388-403. 5. Wang C, Ba Y, Ni J, et al. Role of telemedicine intervention in the treatment of patients with chronic heart failure: A systematic review and meta-analysis. Anatol J Cardiol 2024;28(4):177-86. 6. Wańczura P, Aebisher D, Wiśniowski M, et al. Telemedical Intervention and Its Effect on Quality of Life in Chronic Heart Failure Patients: The Results from the Telemedicine and e-Health Solution Pilot Program. J Clin Med. 2024; 13:2604. 7. Azimi, I., Taherkhani, A., Rahmani, A.M., et al. Missing data resilient decision-making for healthcare IoT through personalization: A case study on maternal health. Future Gener Comput Syst. 2019; 96:297-308. 8. Tefera YG, Abegaz TM, Abebe TB, et al. The changing trend of cardiovascular disease and its clinical characteristics in Ethiopia: a hospital-based observational study. Vasc Health Risk Manag. 2017; 13:143-151. 9. Khezerlou Z, Aghakhani, N., Cheraghi, R., et al. Effect of self-care education via distance learning and the reversal method on self-care behaviors and quality of life in patients with heart failure: A quasi-experimental study. J Nurs Adv Clin Sci. 2025;2(2):63-70.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

2 de marzo de 2026

Finalización primaria (Estimado)

1 de julio de 2026

Finalización del estudio (Estimado)

21 de agosto de 2026

Fechas de registro del estudio

Enviado por primera vez

10 de junio de 2026

Primero enviado que cumplió con los criterios de control de calidad

10 de junio de 2026

Publicado por primera vez (Actual)

16 de junio de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

17 de junio de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

15 de junio de 2026

Última verificación

1 de junio de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • S/C/038/18
  • 928411 (Identificador de registro: Gudisa Bereda)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir